Neurologists Robert Bermel, MD; Rebecca Cebull, CNP; and Marisa McGinley, DO, discuss where serum neurofilament light and ...
Brain insulin resistance serves as the current thematic focus, reinforcing emerging metabolic-neurologic intersections ...
Welcome to NeurologyLive® 's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive 's widespread coverage in ...
The FDA was busy in September 2026, issuing a number of decisions on potential new therapies, including approvals, clearances ...
Neurologists Robert Bermel, MD; Rebecca Cebull, CNP; and Marisa McGinley, DO, discuss where serum neurofilament light and GFAP fit into MS care today and why the field is still waiting on a biomarker ...
Overall, fluctuating symptom control was the most commonly cited reason for discontinuing a prior therapy, identified by 57% of providers, while preference for a consistent treatment schedule was the ...
Former NASCAR driver Darrell Waltrip recently announced a diagnosis of frontotemporal dementia (FTD). Waltrip, a 3-time ...
Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a ...
Tasimelteon advanced sleep onset by 42.5 minutes versus 5.4 minutes with placebo in DSWPD, meeting the primary endpoint with ...
Congressional passage would extend ACT for ALS programs and associated research grants through FY2031, sustaining federal ...
Cerebral palsy (CP) is the most common motor disability of childhood, a group of permanent movement disorders caused by a ...
FcRn blockade with nipocalimab necessitates pregnancy surveillance because placental FcRn drives maternal–fetal IgG transfer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results